A novel neuroprotective cholinesterase-monoamine oxidase inhibitor for treatment of dementia and depression in Parkinson’s disease
Ageing and Neurodegenerative Diseases · 2022
DOI: 10.20517/and.2021.09 ↗Kurz gefasst
Fachartikel in der Zeitschrift Ageing and Neurodegenerative Diseases, 2022. Verfasst von Wei Liu und 2 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref). Gefördert von: Youdim Pharmaceuticals.
Themen: Depression, Demenz
Abstract (Originalsprache)
The current novel therapeutic approach suggests that multi-targeted compounds, with diverse biological activities but a single set of bioavailability and pharmacokinetics, will be significantly more advantageous in the treatment of the complex pathology of Parkinson’s diseases (PD) than traditional therapies. This review introduces a novel cholinesterase (ChE)-monoamine oxidase (MAO) inhibitor, namely MT-031, which was designed by amalgamating the propargyl moiety of the irreversible selective MAO-B inhibitor and neuroprotective/neurorestorative anti-Parkinsonian drug, rasagiline, into the methylamino position of the ChE inhibitor anti-AD drug, rivastigmine. MT-031 possesses neuroprotective, cognition enhancing, anti-depressant, and anti-inflammatory properties both in vitro and in vivo. Altogether, these findings suggest that MT-031 may be a potential treatment for combating PD and associated dementia and depression.
Förderung
- Youdim Pharmaceuticals
Zitieren
APA
Liu, W., Wang, Y., & Youdim, M. B. H. (2022). A novel neuroprotective cholinesterase-monoamine oxidase inhibitor for treatment of dementia and depression in Parkinson’s disease. Ageing and Neurodegenerative Diseases. https://doi.org/10.20517/and.2021.09
Vancouver
Liu W, Wang Y, Youdim MBH. A novel neuroprotective cholinesterase-monoamine oxidase inhibitor for treatment of dementia and depression in Parkinson’s disease. Ageing and Neurodegenerative Diseases. 2022. doi:10.20517/and.2021.09
BibTeX
@article{Liu2022,
author = {Liu, Wei and Wang, Yuqiang and Youdim, Moussa B. H.},
title = {A novel neuroprotective cholinesterase-monoamine oxidase inhibitor for treatment of dementia and depression in Parkinson’s disease},
journal = {Ageing and Neurodegenerative Diseases},
year = {2022},
doi = {10.20517/and.2021.09}
}
EUVIMED